Dr. Douglas Lappi, Chief Scientific Officer, Advanced Targeting Systems The field of targeted toxins has made enormous strides in the years since Advanced Targeting Systems introduced the first research targeted toxin in 1994. We now offer 16 different targeted toxins, with more on the way. The number of important papers in high impact journals continues […]

In September, Advanced Targeting Systems received two Small Business Innovation Research (SBIR) awards from the National Institutes of Health. The first is a Phase II grant from the National Institute of Neurological Disorders and Stroke. This project continues a collaboration with Drs. Joanne Berger-Sweeney (Wellesley College) and Mark Baxter (Harvard University) to further develop the

Dr. Robert Sloviter, University of Arizona, contributes this issue’s article from the laboratories of ATS customers. Dr. Sloviter summarizes his research with SSP-saporin, which he and his graduate student Jennifer Martin used to examine the role of inhibitory neurons in maintaining normal network excitability. The mammalian hippocampus is perhaps the most intensely studied brain region

Advanced Targeting Systems announces the release of its new, very exciting targeted toxin, dermorphin-SAP. It is a conjugate of the mu opioid receptor (MOR) agonist dermorphin and the ribosome-inactivating protein, saporin. Its cytotoxicity to cells that express the MOR promise to make it an important tool in the discovery and definition of the role of